|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: SNHG25 |
Gene summary for SNHG25 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | SNHG25 | Gene ID | 105376843 |
| Gene name | small nucleolar RNA host gene 25 | |
| Gene Alias | SNHG25 | |
| Cytomap | 17q23.3 | |
| Gene Type | ncRNA | GO ID | NA | UniProtAcc | NA |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 105376843 | SNHG25 | GSM4909282 | Human | Breast | IDC | 1.02e-07 | -3.58e-01 | -0.0288 |
| 105376843 | SNHG25 | GSM4909287 | Human | Breast | IDC | 4.26e-06 | -2.91e-01 | 0.2057 |
| 105376843 | SNHG25 | GSM4909288 | Human | Breast | IDC | 1.74e-02 | -4.07e-01 | 0.0988 |
| 105376843 | SNHG25 | GSM4909291 | Human | Breast | IDC | 2.89e-02 | -3.20e-01 | 0.1753 |
| 105376843 | SNHG25 | GSM4909293 | Human | Breast | IDC | 1.74e-02 | -2.16e-01 | 0.1581 |
| 105376843 | SNHG25 | GSM4909297 | Human | Breast | IDC | 1.88e-10 | -3.24e-01 | 0.1517 |
| 105376843 | SNHG25 | GSM4909302 | Human | Breast | IDC | 2.30e-02 | -2.72e-01 | 0.1545 |
| 105376843 | SNHG25 | GSM4909309 | Human | Breast | IDC | 6.07e-10 | -3.63e-01 | 0.0483 |
| 105376843 | SNHG25 | GSM4909311 | Human | Breast | IDC | 4.92e-18 | 3.13e-01 | 0.1534 |
| 105376843 | SNHG25 | GSM4909312 | Human | Breast | IDC | 1.68e-05 | -2.74e-01 | 0.1552 |
| 105376843 | SNHG25 | GSM4909317 | Human | Breast | IDC | 5.91e-03 | -2.96e-01 | 0.1355 |
| 105376843 | SNHG25 | GSM4909319 | Human | Breast | IDC | 1.57e-25 | 9.28e-02 | 0.1563 |
| 105376843 | SNHG25 | GSM4909320 | Human | Breast | IDC | 6.91e-07 | 4.61e-01 | 0.1575 |
| 105376843 | SNHG25 | GSM4909321 | Human | Breast | IDC | 3.51e-05 | -2.35e-01 | 0.1559 |
| 105376843 | SNHG25 | brca1 | Human | Breast | Precancer | 3.75e-10 | -3.80e-01 | -0.0338 |
| 105376843 | SNHG25 | brca2 | Human | Breast | Precancer | 1.80e-06 | -3.27e-01 | -0.024 |
| 105376843 | SNHG25 | brca3 | Human | Breast | Precancer | 2.53e-10 | -3.59e-01 | -0.0263 |
| 105376843 | SNHG25 | M1 | Human | Breast | IDC | 2.11e-34 | 9.54e-01 | 0.1577 |
| 105376843 | SNHG25 | NCCBC14 | Human | Breast | DCIS | 5.09e-10 | 4.14e-01 | 0.2021 |
| 105376843 | SNHG25 | NCCBC2 | Human | Breast | DCIS | 4.43e-06 | 4.61e-01 | 0.1554 |
| Page: 1 2 3 4 5 6 7 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Breast |  | IDC: Invasive ductal carcinoma |
| DCIS: Ductal carcinoma in situ | ||
| Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers | ||
| GC |  | CAG: Chronic atrophic gastritis |
| CAG with IM: Chronic atrophic gastritis with intestinal metaplasia | ||
| CSG: Chronic superficial gastritis | ||
| GC: Gastric cancer | ||
| SIM: Severe intestinal metaplasia | ||
| WIM: Wild intestinal metaplasia | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| Page: 1 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |